26 Investigating boron neutron capture therapy for the treatment of glioblastoma

Clicks: 16
ID: 326728
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #232 of 287 articles by views in journal of neuro-oncology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 287 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Introduction With an average survival of 12-18 months, glioblastoma is the most commonly diagnosed malignant brain tumour in adults. Despite treatment advances, survival outcomes have shown minimal improvements over the past decades. Persistent treatment resistance, and disease recurrence, highlight the need for alternative, more effective, therapies to be explored. Driven by advances in accelerator-based neutron sources and next-generation boron compounds, boron neutron capture therapy (BNCT) has re-emerged as a promising alternative therapy for glioblastoma. BNCT involves loading tumour cells with boron-10 and irradiating the tumour with thermal neutrons, which releases high-LET particles that deposit their energy over a very short distance, selectively killing tumour cells while sparing healthy tissue. With Birmingham hosting the UK’s first and only neutron source, this work is well positioned to generate mechanistic insights that will drive BNCT development for effectively treating glioblastoma. Methods Human glioblastoma cell lines were treated with a panel of boron-10 compounds. MTTs, clonogenics, and spheroid growth assays were performed to assess toxicity, and baseline X-ray radiosensitisation. These experiments have been replicated with neutrons to evaluate BNCT efficacy. Boron compound uptake was measured using ICP-MS. LAT1 was overexpressed using a LIC-assembled plasmid and knocked down using siRNA. Results Across all boron-10 compounds, minimal toxicity was observed on glioblastoma cells, and as expected no measurable radiosensitisation occurred with X-rays. In contrast, significant glioblastoma cell killing was observed in BNCT reactions where boron uptake was shown. LAT1-dependence studies are ongoing. Conclusions This research establishes a strong foundation for establishing BNCT as a more effective treatment for glioblastoma, and provides a clear pathway for evaluating its optimal efficacy in combination with other targeted drugs/inhibitors. Future work will focus on evaluation of other glioblastoma-specific boron-10 compounds.
Reference Key
openalex_W7204456302 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Bethany Mackinnon
Are you one of these authors? Claim your profile
Journal journal of neuro-oncology
Year 2026
DOI
10.1093/neuonc/noag172.070
URL
https://academic.oup.com/neuro-oncology/article-pdf/28/Supplement_1/noag172.070/70805949/noag172.070.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.